Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Bergwerk, 2021, COVID-19 breakthrough infections in vaccinated health care workers, N Engl J Med, 385, 1474, 10.1056/NEJMoa2109072 Jara, 2021, Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile, N Engl J Med, 385, 875, 10.1056/NEJMoa2107715 Li, 2021, Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study, Emerg Microbes Infect, 10, 1751, 10.1080/22221751.2021.1969291 Tang, 2021, BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar, Nat Med, 27, 2136, 10.1038/s41591-021-01583-4 Swan, 2021, COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact, Sci Rep, 11, 10.1038/s41598-021-94719-y Grohskopf, 2021, Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021–22 influenza season, MMWR Recomm Rep, 70, 1, 10.15585/mmwr.rr7005a1 Lund, 2021, Scent of a vaccine, Science, 373, 397, 10.1126/science.abg9857 Wang, 2019, Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines, mBio, 10, e02180, 10.1128/mBio.02180-19 Chen, 2021, A live attenuated influenza virus-vectored intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 infection, bioRxiv Folegatti, 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet, 396, 467, 10.1016/S0140-6736(20)31604-4 Zhu, 2020, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, Lancet, 395, 1845, 10.1016/S0140-6736(20)31208-3 Walsh, 2020, Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates, N Engl J Med, 383, 2439, 10.1056/NEJMoa2027906 Jackson, 2020, An mRNA vaccine against SARS-CoV-2—preliminary report, N Engl J Med, 383, 1920, 10.1056/NEJMoa2022483 Xia, 2021, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, Lancet Infect Dis, 21, 39, 10.1016/S1473-3099(20)30831-8 Zens, 2016, Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection, JCI Insight, 1, 10.1172/jci.insight.85832 Lau, 2011, The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines, J Virol, 85, 76, 10.1128/JVI.01564-10 He, 2006, Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines, J Virol, 80, 11756, 10.1128/JVI.01460-06 Morabito, 2017, Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung, Mucosal Immunol, 10, 545, 10.1038/mi.2016.48 Treanor, 1999, Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses, Vaccine, 18, 899, 10.1016/S0264-410X(99)00334-5 Treanor, 2003, Immune correlates of protection against influenza in the human challenge model, Dev Biol (Basel), 115, 97 Rose, 2012, Mucosal immunity and nasal influenza vaccination, Expert Rev Vaccines, 11, 595, 10.1586/erv.12.31 Kappler, 2006, Detection of secretory IgA antibodies against gliadin and human tissue transglutaminase in stool to screen for coeliac disease in children: validation study, BMJ, 332, 213, 10.1136/bmj.38688.654028.AE Sekine, 2020, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell, 183, 158, 10.1016/j.cell.2020.08.017 Cañete, 2020, COVID-19 makes B cells forget, but T cells remember, Cell, 183, 13, 10.1016/j.cell.2020.09.013 Vesikari, 2006, A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine, Pediatr Infect Dis J, 25, 590, 10.1097/01.inf.0000220229.51531.47 Wortham, 2020, Characteristics of persons who died with COVID-19—United States, February 12–May 18, 2020, MMWR Morb Mortal Wkly Rep, 69, 923, 10.15585/mmwr.mm6928e1 Killerby, 2020, Characteristics associated with hospitalization among patients with COVID-19—Metropolitan Atlanta, Georgia, March–April 2020, MMWR Morb Mortal Wkly Rep, 69, 790, 10.15585/mmwr.mm6925e1 Tenforde, 2021, Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years—United States, January–March 2021, MMWR Morb Mortal Wkly Rep, 70, 674, 10.15585/mmwr.mm7018e1 Ranzani, 2021, Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study, BMJ, 374